Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1987 May;31(5):808–810. doi: 10.1128/aac.31.5.808

Failure to demonstrate a consistent in vitro bactericidal effect of trimethoprim-sulfamethoxazole against enterococci.

A Najjar, B E Murray
PMCID: PMC174838  PMID: 3111362

Abstract

Controversy exists as to the in vitro and in vivo activities of trimethoprim-sulfamethoxazole (TMP-SMX) against enterococci. In this study, we investigated the in vitro activity of TMP-SMX in the type of Mueller-Hinton broth previously reported to give the lowest MICs and MBCs with enterococci. In all instances, MICs were less than or equal to 0.5 microgram/ml. The majority of tests showed MBCs of greater than 32 micrograms/ml, although there was some effect from varying the inoculum and the length of incubation after subculturing. Minor differences were noted when tests were repeated and between the results from microdilution and macrodilution tests and those obtained by the time-kill method. These results, as well as other reports, suggest that TMP-SMX should not be considered a reliable bactericidal agent against enterococci.

Full text

PDF
808

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Crider S. R., Colby S. D. Susceptibility of enterococci to trimethoprim and trimethoprim-sulfamethoxazole. Antimicrob Agents Chemother. 1985 Jan;27(1):71–75. doi: 10.1128/aac.27.1.71. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Goodhart G. L. In vivo v in vitro susceptibility of enterococcus to trimethoprim-sulfamethoxazole. A pitfall. JAMA. 1984 Nov 16;252(19):2748–2749. [PubMed] [Google Scholar]
  3. Herzstein J., Ryan J. L., Mangi R. J., Greco T. P., Andriole V. T. Optimal therapy for enterococcal endocarditis. Am J Med. 1984 Feb;76(2):186–191. doi: 10.1016/0002-9343(84)90772-1. [DOI] [PubMed] [Google Scholar]
  4. Mederski-Samoraj B. D., Murray B. E. High-level resistance to gentamicin in clinical isolates of enterococci. J Infect Dis. 1983 Apr;147(4):751–757. doi: 10.1093/infdis/147.4.751. [DOI] [PubMed] [Google Scholar]
  5. Murray B. E., Church D. A., Wanger A., Zscheck K., Levison M. E., Ingerman M. J., Abrutyn E., Mederski-Samoraj B. Comparison of two beta-lactamase-producing strains of Streptococcus faecalis. Antimicrob Agents Chemother. 1986 Dec;30(6):861–864. doi: 10.1128/aac.30.6.861. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Murray B. E., Mederski-Samaroj B. Transferable beta-lactamase. A new mechanism for in vitro penicillin resistance in Streptococcus faecalis. J Clin Invest. 1983 Sep;72(3):1168–1171. doi: 10.1172/JCI111042. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Murray B. E., Tsao J., Panida J. Enterococci from Bangkok, Thailand, with high-level resistance to currently available aminoglycosides. Antimicrob Agents Chemother. 1983 Jun;23(6):799–802. doi: 10.1128/aac.23.6.799. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Tofte R. W., Solliday J. A., Crossley K. B. Susceptibilities of enterococci to twelve antibiotics. Antimicrob Agents Chemother. 1984 Apr;25(4):532–533. doi: 10.1128/aac.25.4.532. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Wilson W. R., Wilkowske C. J., Wright A. J., Sande M. A., Geraci J. E. Treatment of streptomycin-susceptible and streptomycin-resistant enterococcal endocarditis. Ann Intern Med. 1984 Jun;100(6):816–823. doi: 10.7326/0003-4819-100-6-816. [DOI] [PubMed] [Google Scholar]
  10. Zervos M. J., Schaberg D. R. Reversal of the in vitro susceptibility of enterococci to trimethoprim-sulfamethoxazole by folinic acid. Antimicrob Agents Chemother. 1985 Sep;28(3):446–448. doi: 10.1128/aac.28.3.446. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES